T-ALL Cells as Tool Cells for CAR T Therapy

Area of Science:

• Immunotherapy
• Hematologic Malignancies
• Cancer Cell Engineering

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise for hematologic malignancies but faces challenges in T-cell malignancies like T-ALL.
• T-ALL cells share antigens with normal T cells, complicating CAR T-cell therapy due to purification difficulties, product contamination, and CAR T-cell fratricide.

Purpose of the Study:

• To engineer T-ALL cells to express CARs (CAR T-ALL) to prevent fratricide and effectively eliminate tumor cells.
• To investigate the potential of engineered T-ALL cells as therapeutic 'tool cells' for broader cancer treatment.

Main Methods:

• Transduction of T-ALL cells with CARs to assess fratricide and tumor cell killing capabilities.
• Development of a Tet-On inducible CD99 CAR system in Jurkat cells to control CAR T-ALL fratricide and therapeutic effects.
• Evaluation of engineered Jurkat cells expressing CARs targeting antigens on other cancer cell lines for their cytotoxic potential.

Main Results:

• Initial attempts showed CAR T-ALL cells undergoing fratricide, but they could selectively kill T-ALL cell lines.
• The Tet-On inducible CD99 CAR system successfully prevented fratricide in engineered Jurkat cells, allowing controlled killing.
• Engineered Jurkat cells expressing CARs targeting antigens on other cancer cells demonstrated efficacy in killing diverse cancer cell lines.

Conclusions:

• Engineered T-ALL cells, particularly with inducible CAR systems, can overcome fratricide and function as effective cancer-killing tool cells.
• This novel approach offers a feasible and controllable therapeutic strategy for various cancers, expanding the application of CAR technology.